Renaissance Technologies
SNDX icon

Renaissance Technologies’s Syndax Pharmaceuticals SNDX Stock Holding History

Renaissance Technologies’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.03M Sell
321,600
-176,600
-35% -$3.67M 0.01% 1260
2026
Q1 		$11.6M Sell
498,200
-46,600
-9% -$1.01M 0.02% 897
2025
Q4 		$11.4M Sell
544,800
-315,700
-37% -$5.51M 0.02% 853
2025
Q3 		$13.2M Buy
860,500
+22,800
+3% +$298K 0.02% 939
2025
Q2 		$7.85M Buy
837,700
+156,273
+23% +$1.72M 0.01% 1228
2025
Q1 		$8.37M Buy
681,427
+462
+0.1% +$6.52K 0.01% 1104
2024
Q4 		$9M Buy
+680,965
New +$11.7M 0.01% 1082
2024
Q3 		– Sell
-214,300
Closed -$4.4M – 3854
2024
Q2 		$4.4M Buy
214,300
+135,200
+171% +$2.83M 0.01% 1390
2024
Q1 		$1.88M Buy
+79,100
New +$1.76M ﹤0.01% 2071
2023
Q4 		– Sell
-218,300
Closed -$3.17M – 4100
2023
Q3 		$3.17M Buy
+218,300
New +$4.13M 0.01% 1570
2023
Q1 		– Sell
-81,200
Closed -$2.07M – 4357
2022
Q4 		$2.07M Buy
+81,200
New +$1.89M ﹤0.01% 2046
2022
Q2 		– Sell
-182,100
Closed -$3.17M – 4548
2022
Q1 		$3.17M Buy
+182,100
New +$3.07M ﹤0.01% 1884
2020
Q3 		– Sell
-94,700
Closed -$1.4M – 3661
2020
Q2 		$1.4M Sell
94,700
-392,900
-81% -$5.98M ﹤0.01% 2373
2020
Q1 		$5.35M Sell
487,600
-7,900
-2% -$74.1K 0.01% 1520
2019
Q4 		$4.35M Sell
495,500
-1,500
-0.3% -$11K ﹤0.01% 1940
2019
Q3 		$3.71M Buy
497,000
+65,100
+15% +$593K ﹤0.01% 1961
2019
Q2 		$4.02M Buy
431,900
+117,300
+37% +$855K ﹤0.01% 1932
2019
Q1 		$1.65M Buy
314,600
+85,500
+37% +$488K ﹤0.01% 2412
2018
Q4 		$1.02M Sell
229,100
-50,200
-18% -$275K ﹤0.01% 2561
2018
Q3 		$2.26M Buy
279,300
+237,000
+560% +$1.69M ﹤0.01% 2214
2018
Q2 		$297K Sell
42,300
-10,200
-19% -$100K ﹤0.01% 2965
2018
Q1 		$747K Buy
52,500
+26,800
+104% +$284K ﹤0.01% 2778
2017
Q4 		$225K Buy
+25,700
New +$254K ﹤0.01% 3102

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Renaissance Technologies's SNDX Position: Q2 2026 in Review

Renaissance Technologies reduced its Syndax Pharmaceuticals (SNDX) stake by 35% in Q2 2026, selling an estimated $3.67M and leaving 321,600 shares worth $7.03M. The position accounts for 0.01% of the portfolio, ranked #1260.

Renaissance Technologies first reported a position in SNDX in Q4 2017 and has held it in 23 quarters since. The position peaked at $13.2M in Q3 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Renaissance Technologies held 321,600 shares of Syndax Pharmaceuticals worth $7.03M as of Q2 2026.
  • Renaissance Technologies sold 176,600 Syndax Pharmaceuticals shares in Q2 2026, an estimated $3.67M.
  • Syndax Pharmaceuticals made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1260 holding.
  • Renaissance Technologies first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 23 quarters since.
  • Renaissance Technologies's Syndax Pharmaceuticals position peaked at $13.2M in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.